Browse the evidence

Tirzepatide induces significant, dose-dependent weight loss in patients with obesity or type 2 diabetes, with non-diabetic individuals experiencing greater absolute weight reduction than diabetic individuals at equivalent doses.

Tirzepatide is a highly effective treatment for weight loss, with higher doses (15 mg) producing the greatest results. Non-diabetic patients tend to lose more weight than diabetic patients at the same dose. The most common barrier is gastrointestinal side effects like nausea, which are dose-dependent but typically manageable and do not lead to serious health risks.

Tirzepatide increases the likelihood of achieving clinically meaningful weight loss thresholds (≥5%, ≥10%, ≥15%) in a dose-dependent manner, with 15 mg showing the highest odds ratios for all thresholds.

Higher doses of tirzepatide significantly increase your chances of losing 5%, 10%, or 15% of your body weight. The 15 mg dose offers the highest probability of achieving these milestones compared to lower doses.

Semaglutide (2.4 mg weekly) produces significantly greater weight loss than liraglutide (3.0 mg daily), orlistat, and phentermine in obese individuals.

If you have obesity or overweight with related health risks, Semaglutide (2.4 mg weekly) is currently the most effective pharmacological option for weight loss, significantly outperforming Liraglutide, Orlistat, and Phentermine. You must start at a low dose (0.25 mg) and increase it every 4 weeks to minimize stomach side effects. This medication works best when combined with diet and exercise changes.

Once-weekly subcutaneous semaglutide at 2.4 mg is effective and safe for weight loss in non-diabetic adults and adolescents with overweight or obesity, demonstrating superiority over both placebo and daily liraglutide.

For non-diabetic adults and adolescents with obesity, once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle changes is a highly effective treatment for significant weight loss. It is superior to placebo and daily liraglutide. While gastrointestinal side effects like nausea are common, they often subside over time. This treatment is FDA-approved and supported by robust clinical trials.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant, dose-dependent weight loss and HbA1c reduction in overweight and obese adults with type 2 diabetes, with efficacy increasing at doses of 5mg, 10mg, and 15mg administered once weekly.

If you have type 2 diabetes and are overweight or obese, Tirzepatide is a highly effective, once-weekly injection that helps you lose significant weight and lower your blood sugar. The higher the dose (up to 15mg), the more weight you tend to lose. While you might experience side effects like nausea or diarrhea, especially at higher doses, most people get used to it. It is more effective than many existing obesity medications.

Tirzepatide administration significantly reduces body weight in overweight and obese individuals (BMI ≥28 kg/m²) compared to control, with the magnitude of weight loss being dose-dependent.

If you have a BMI of 28 or higher, Tirzepatide is a clinically proven option for significant weight loss. It works by mimicking hormones that regulate blood sugar and appetite. You take it as a once-weekly injection, starting at a low dose (2.5mg) and increasing to 5mg, 10mg, or 15mg depending on your response. Expect some gastrointestinal side effects like nausea or diarrhea, especially at higher doses, but most people tolerate it well. The higher the dose, the more weight you tend to lose.

Tirzepatide significantly reduces HbA1c levels in individuals with Type 2 Diabetes, with the effect being dose-dependent.

For those managing Type 2 Diabetes, Tirzepatide offers a powerful tool to lower blood sugar levels (HbA1c). It works by helping your pancreas release insulin when needed and stopping the liver from making too much sugar. Like with weight loss, higher doses lead to greater HbA1c reductions. This makes it a viable option for patients who need better glycemic control alongside weight management.

Weekly subcutaneous semaglutide at 2.4 mg reduces the risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in patients with obesity or overweight and preexisting cardiovascular disease, regardless of diabetes status.

If you have heart disease and are overweight or obese, but do not have diabetes, adding once-weekly semaglutide (2.4 mg) to your standard heart care significantly lowers your risk of heart attack, stroke, or heart-related death. The treatment involves a slow buildup of the dose over 16 weeks to manage side effects like nausea. While it works well for most, be aware that gastrointestinal issues are the main reason people stop taking it.

Once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle intervention produces sustained, clinically significant weight loss in adults with overweight or obesity, significantly outperforming placebo.

If you have obesity or overweight with related health conditions, adding once-weekly semaglutide (2.4 mg) to a reduced-calorie diet and exercise program can lead to substantial, sustained weight loss (averaging nearly 15% of body weight) compared to lifestyle changes alone. Be prepared for potential gastrointestinal side effects like nausea, which usually improve over time, and adhere to the titration schedule to minimize discomfort.

Subcutaneous semaglutide at a maintenance dose of 2.4 mg once weekly produces clinically significant weight loss (mean reduction ~14-16%) in non-diabetic adults with obesity or overweight, significantly outperforming placebo.

For non-diabetic adults with obesity or overweight, weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, achieving an average 15% body weight reduction. This is significantly better than placebo or other existing medications. Treatment involves a gradual dose increase over 16 weeks to minimize side effects, combined with a calorie-restricted diet and exercise. Patients should be aware that stopping the medication often leads to weight regain, suggesting it may be a long-term therapy.

Once-weekly subcutaneous semaglutide (specifically the 2.4 mg dose) produces substantial, sustained weight loss (mean reduction ~14.9%) and significant improvements in cardiometabolic risk factors (HbA1c, lipids, blood pressure) in adults with overweight or obesity, with an acceptable safety profile characterized by mild-to-moderate gastrointestinal side effects.

If you have obesity or overweight with comorbidities, once-weekly semaglutide (2.4 mg) is a highly effective medical treatment that can help you lose nearly 15% of your body weight and improve heart health markers like blood pressure and cholesterol. While you may experience temporary stomach issues like nausea when starting, these usually get better as your body adjusts. It is not a quick fix but a long-term management tool for a chronic condition, comparable to how medication manages high blood pressure.

A nutritional supplement is considered ergogenic only if peer-reviewed human studies demonstrate it significantly enhances exercise performance or muscle hypertrophy with long-term ingestion, not just acute effects or preclinical data.

Do not be misled by supplements that claim to work instantly or are only supported by animal studies. Look for products that have been tested in humans over weeks or months of training. The most reliable supplements are those with long-term efficacy data showing they help you build muscle or perform better consistently over time.

High consumption of dietary sodium increases systolic blood pressure (SBP) and the risk of fatal cardiovascular disease (CVD).

Reduce your sodium intake. High sodium raises blood pressure and increases the risk of fatal heart disease. Aim for lower sodium levels by cooking at home, reading labels, and using herbs and spices for flavor.

High consumption of trans-fats causes an increased risk of coronary heart disease (CHD).

Avoid trans-fats. They are linked to an increased risk of coronary heart disease. Check labels for 'partially hydrogenated oils' and choose foods with healthier fats like olive oil, nuts, and seeds.

Obesity (or preobesity) is a primary upstream risk factor for Type 2 Diabetes, contributing to more than 50% of global T2D disability-adjusted life years.

Excess body weight is the single biggest driver of Type 2 Diabetes risk globally. Losing weight, even modestly, can significantly reduce your risk of developing diabetes and its complications, as it directly addresses the root cause of insulin resistance.

Subcutaneous semaglutide (2.4 mg once weekly) produces significant weight loss (mean 14.9% body weight reduction in STEP 1) and improves cardiometabolic markers (waist circumference, blood pressure, HbA1c, lipids) compared to placebo in adults with obesity.

For adults with obesity, subcutaneous semaglutide (2.4 mg weekly) is a highly effective treatment that reduces body weight by approximately 15% and improves cardiovascular risk factors. It is well-tolerated, though gastrointestinal side effects like nausea are common; these can be mitigated by slow dose escalation and dietary adjustments. It is superior to other weight loss medications in clinical trials.

The one-repetition maximum (1RM) test demonstrates good-to-excellent test-retest reliability across diverse populations, exercise types, and training statuses, making it a valid tool for assessing muscular strength.

Use the 1RM test to measure your maximum strength. It is a reliable tool regardless of your gender, age, or training experience. You do not need multiple familiarization sessions to get a reliable result, and it works for both upper and lower body exercises. Trust the numbers, as they are consistent.

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide facilitate significant weight loss and maintenance by acting on central nervous system receptors to reduce appetite and hunger, increase satiety, and alter food reward pathways, rather than solely through gastrointestinal side effects.

GLP-1 medications like semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda) are highly effective for weight loss because they work on your brain to reduce hunger and increase fullness, not just by making you sick. They are taken by injection, either daily or weekly, and work best when combined with a healthy diet and exercise. Side effects like nausea are common at first but usually go away, and you can manage them by starting with a low dose and increasing it slowly.

Replacing saturated fat with refined carbohydrates provides no cardiovascular benefit, whereas substituting polyunsaturated fats (PUFA) for saturated fat or refined carbohydrates significantly reduces cardiovascular disease risk.

Stop focusing solely on cutting saturated fat. If you reduce saturated fat, make sure you replace it with polyunsaturated fats (like those in nuts, seeds, and vegetable oils) rather than refined carbs (like white bread or sugar). Replacing saturated fat with refined carbs offers no heart benefit, but replacing it with PUFA significantly lowers your risk of heart disease.

Mediterranean dietary patterns supplemented with extra-virgin olive oil or mixed nuts significantly reduce the risk of major cardiovascular events (myocardial infarction, stroke, or death) compared to a control diet reduced in dietary fat.

Adopt a Mediterranean-style diet by adding specific healthy fats. Aim for 50 grams of extra-virgin olive oil or 30 grams of mixed nuts daily. This specific supplementation within a Mediterranean pattern has been shown to reduce heart attacks, strokes, and death by 30% compared to a standard low-fat diet.

Trans fats from partially hydrogenated oils have no safe level of consumption and should be limited as much as possible due to their adverse effects on multiple cardiovascular risk factors.

Avoid trans fats completely. Check food labels for 'partially hydrogenated oils' and avoid products containing them. There is no safe amount of trans fat, and they significantly increase heart disease risk by raising bad cholesterol, lowering good cholesterol, and increasing inflammation.

Once-weekly subcutaneous semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE), heart failure composite endpoints, cardiovascular death, and all-cause death in patients with atherosclerotic cardiovascular disease and obesity, regardless of whether they have heart failure with preserved or reduced ejection fraction.

If you have heart disease and are overweight or obese, especially if you have heart failure, asking your doctor about once-weekly semaglutide (2.4 mg) could significantly lower your risk of heart attacks, strokes, heart failure hospitalizations, and death. This benefit applies whether your heart pumps strongly or weakly, and it is safe to use alongside your current heart failure medications.

Group-based self-management education for Type 2 diabetes significantly improves HbA1c, body weight, waist circumference, triglycerides, and diabetes knowledge compared to usual care or individual education, with effects persisting up to 48 months.

Join a structured group education program for Type 2 diabetes rather than relying solely on individual visits. Look for programs led by health professionals (doctors, dietitians, nurses) or multidisciplinary teams, as these show significant improvements in blood sugar (HbA1c), weight, and knowledge. The benefits can last for years, with HbA1c reductions of 0.3-0.9% observed up to 48 months.

Repeated bouts of mechanical overload (resistance training) induce skeletal muscle hypertrophy primarily through transient increases in mTORC1 signaling, which elevates muscle protein synthesis rates, alongside expanded translational capacity via ribosome biogenesis and increased satellite cell abundance/myonuclear accretion.

To build muscle, you must consistently apply mechanical overload (resistance training) to your muscles. This triggers internal cellular signals (mTORC1) that increase protein synthesis and add new nuclei to muscle fibers. Focus on progressive resistance training over 8-16 weeks to achieve significant mass gains (5-20%). Do not rely solely on hormones or 'pumps'; the mechanical stimulus is the primary driver.